Chengdu Olymvax Biopharmaceuticals Inc. Class ASSE: 688319

Announcement on Voluntary Disclosure of Initiating Phase III Clinical Trial of the Quadrivalent Influenza Virus Split Vaccine (MDCK Cells) and Enrolling the First Subject

· Issued by Chengdu Olymvax Biopharmaceuticals Inc. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of Initiating Phase III Clinical Trial of the Quadrivalent Influenza Virus Split Vaccine (MDCK Cells) and Enrolling the First Subject

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis